Share Purchase Plan Booklet & Option Prospectus
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
19 April 2023
SPP Booklet and Option Prospectus
Melbourne, Australia; 19 April 2023: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to lodge the attached Letter to
Shareholders, Share Purchase Plan Booklet and Option Prospectus.
-ENDSAuthorised for release by Dr Ross Macdonald, Managing Director & CEO
CONTACTS:
Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused
on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™
overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell
known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal
stem cells (MSCs), at commercial scale without the limitation of multiple donors.
Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for
the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical
trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase
3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology
in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia,
idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release
syndrome.
Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated
registry service provider, Automic Group.
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: +613 7067 6940 E: info@cynata.com
ABN – 98 104 037 372
19 April 2023
Dear Shareholder
Cynata Therapeutics Limited Share Purchase Plan and SPP Option Offer
On behalf of the Board of Cynata Therapeutics Limited ACN 104 037 372) (Cynata or the Company),
I am pleased to offer you the opportunity to apply for New Shares through participation in a share
purchase plan (SPP).
The SPP
The SPP allows Eligible Shareholders, being Shareholders as at the Record Date of 5 April 2023 with
a registered address in Australia or New Zealand, the opportunity to subscribe for up to $30,000 worth
of New Shares without paying brokerage or other transaction costs.
The Share Purchase Plan is being conducted as part of a Capital Raising to raise up to approximately
$7.04 million, comprising the SPP to raise up to a maximum of $2 million (which is subject to scaleback)
and the placement to raise $5.04 million, which was announced on 6 April 2023 (Placement).
The SPP is being undertaken at the SPP Offer Price, which is the lower of:
•
•
the offer price under the Placement, being $0.215; and
the price representing a 2.5% discount to the volume weighted average price of Shares during
the five trading days up to and including the Closing Date of the SPP, rounded to the nearest half
cent,
provided that the SPP Offer Price can be no lower than the lowest price permitted under ASX Listing
Rule 7.2, Exception 5.
The SPP will not be underwritten.
The offer of New Shares under the SPP is being undertaken via the SPP Booklet.
SPP Option Offer
Eligible Shareholders are also entitled to apply for one free attaching option (Option) for every two New
Shares subscribed for under the SPP via the SPP Option Offer. The Options will be exercisable at
$0.30 (30 cents), expiring on 1 April 2025, and the Company will apply for the Options to be quoted on
ASX.
The SPP Option Offer is being made under a Prospectus that is being provided to Eligible Shareholders.
The SPP Option Offer is conditional on Shareholder approval at the Company’s Extraordinary General
Meeting to be held in Melbourne on or around 25 May 2023 (Meeting). A separate Notice of Meeting
will be dispatched to Shareholders in connection with the Meeting, and I encourage all Shareholders to
carefully read the Notice of Meeting and vote at the Meeting.
If Shareholder approval is not obtained, or if the Options do not meet ASX’s quotation conditions, the
offer and issue of Shares under the SPP and this Booklet may proceed, however the issue Options
under the SPP Option Offer and the Prospectus may not occur. In these circumstances, SPP
participants may receive New Shares under the SPP but not Options under the SPP Option Offer.
Timetable
The indicative timetable for the SPP and SPP Option Offer are set out below.
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: +613 7067 6940 E: info@cynata.com
ABN – 98 104 037 372
Event
Date (2023)
SPP Record Date
Wednesday, 5 April
Capital Raising announced
Thursday, 6 April
Investor Presentation and ASX Announcement
lodged with ASX
Settlement of Unconditional Placement (other
than Bioscience Managers)
Friday, 14 April
Issue and trading of Shares under the
Unconditional
Placement
(other
than
Bioscience Managers)
Monday, 17 April
Despatch of SPP Offer Booklet
Wednesday, 19 April
SPP opens
Prospectus lodged with ASIC and ASX and
Options offer opens
Settlement and issue of Shares to Bioscience
Managers under Unconditional Placement
Monday, 24 April
Despatch of Notice of Meeting
Monday, 24 April
SPP closes
Monday, 8 May
Announcement of results of SPP
Wednesday, 10 May
Issue of new Shares under SPP (other than
SPP Shortfall Shares)
Thursday, 11 May
Extraordinary General Meeting
Thursday, 25 May
Settlement of Director Placement
Tuesday, 30 May
Allotment of Shares under the Director
Placement
Wednesday, 31 May
Allotment of Options (subject to Shareholder
approval and ASX quotation condition being
met)
Cynata reserves the right to vary these times and dates (other than in respect of events that have already occurred) in its absolute
discretion by sending a revised timetable to ASX. All times are Melbourne times. CYP also reserves the right to accept late applications at
its discretion.
How to apply
If you wish to participate in the SPP and SPP Option Offer, please download the Booklet and Options
Prospectus and follow the instructions contained within the Application Form which accompanies the
Prospectus. You can access your personalised Application Form to apply for New Shares and Options
by taking the following steps:
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: +613 7067 6940 E: info@cynata.com
ABN – 98 104 037 372
1. Go to https://investor.automic.com.au/#/home
2. Log in with your existing username and password or register for an online account
3. Once logged in, click on “Documents and Statements” then “Other Documents”
4. Click on the Booklet, Options Prospectus and Application Form to download
The SPP and SPP Option Offer is expected to close on Monday, 8 May 2023.
The Booklet and Prospectus contain further information regarding the SPP and SPP Option Offer. In
particular, the Prospectus sets out the terms of issue of the Options and describes the risks associated
with an investment in Cynata. Eligible Shareholders should read the Prospectus before making any
decision to invest. The Company is not licensed to provide financial advice and is not providing
investment advice or any recommendation regarding the SPP and SPP Option Offer.
Queries
If you have any queries about how to participate in the SPP and SPP Option Offer, or if you would like
to receive a paper copy of the Booklet and Prospectus, and a paper Application Form, please contact
the Share Registry on 1300 288 664 (toll free within Australia) or +61 2 9698 5414 (International). You
may also contact the Company Secretary on (08) 6377 8043. You should consult your professional
adviser when deciding whether or not to participate in the SPP and SPP Option Offer.
Thank you for your support of Cynata
Dr Geoff Brooke
Chairman
Cynata Therapeutics Limited
Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: +613 7067 6940 E: info@cynata.com
ABN – 98 104 037 372
Capitalised terms used in this Booklet have the
meanings given to them in the Glossary.
The offer of New Shares under the Share Purchase
Plan is made in accordance with ASIC Corporations
(Share and Interest Purchase Plans) Instrument
2019/547 (“Instrument 2019/547”), which grants relief
from the requirement for the Company to provide
prospectus disclosure in relation to the Share
Purchase Plan. This Booklet is not a prospectus under
Chapter 6D of the Corporations Act.
Cynata Therapeutics Limited
The laws of some countries prohibit or make
impracticable participation in the Share Purchase Plan
by certain overseas Shareholders. Shareholders who
are not resident in Australia or New Zealand will not be
able to participate in the Share Purchase Plan unless
otherwise determined by the Board. The Share
Purchase Plan does not constitute an offer of Shares
for sale in any other jurisdiction.
ACN 104 037 372
Share Purchase Plan Booklet
New Zealand
The New Shares are not being offered or sold to the
public within New Zealand other than to existing
Shareholders at the Record Date with registered
addresses in New Zealand to whom the offer of New
Shares is being made in reliance on the Financial
Markets Conduct (Incidental Offers) Exemption Notice
2016 (New Zealand).
This document is dated 19 April 2023.
This is an important document. Please read it carefully
before making an investment decision in relation to the
Share Purchase Plan.
If you have any questions in relation to how to
participate in the Share Purchase Plan after reading
this Booklet, please contact Automic Registry Services,
the Company’s share registry, from 9.00am to 5.00pm
AEST, Monday to Friday, on 1300 288 664 (toll free
within Australia) or +61 2 9698 5414 (International).
You may also call the Company Secretary on (08) 6377
8043.
If you have any questions in relation to whether an
investment in Cynata Therapeutics Limited through the
Share Purchase Plan is appropriate for you, please
contact your stockbroker, accountant or other
professional adviser.
IMPORTANT NOTICE AND DISCLAIMER
This Booklet does not provide financial advice and has
been prepared without taking account of any person’s
investment objectives, financial situation or particular
needs. You should consider the appropriateness of
participating in the Share Purchase Plan having regard
to your investment objectives, financial situation or
particular needs.
DRAFT
This Booklet has not been registered, filed with or
approved by any New Zealand regulatory authority.
This Booklet is not a product disclosure statement
under New Zealand law and is not required to, and may
not, contain all the information that a product disclosure
statement under New Zealand law is required to
contain.
United States
This Booklet may not be released or distributed in the
United States. The New Shares have not been and will
not be registered under the US Securities Act of 1933
(the “Securities Act”) or the securities laws of any
state or other jurisdiction of the United States. The New
Shares may not be offered, sold or otherwise
transferred in the United States except in a transaction
exempt from, or not subject to, the registration
requirements of the Securities Act and the applicable
securities laws of any state or other jurisdiction in the
United States.
Options
Participants in the Share Purchase Plan are entitled to
apply for Options. The offer of Options is being made
under the Prospectus.
LETTER TO SHAREHOLDERS
Dear Shareholder
Cynata Therapeutics Limited Share Purchase Plan
On behalf of the Board, I am pleased to offer you the opportunity to apply for New Shares through participation in a share
purchase plan (SPP).
The SPP
The SPP allows Eligible Shareholders the opportunity to subscribe for up to $30,000 worth of New Shares without paying
brokerage or other transaction costs.
The Share Purchase Plan is being conducted as part of a Capital Raising to raise up to approximately $7.04 million,
comprising the SPP to raise up to a maximum of $2 million (which is subject to scaleback) and the placement to raise
$5.04 million, which was announced on 6 April 2023 (Placement).
The SPP is being undertaken at the SPP Offer Price, which is the lower of:
•
the offer price under the Placement, being $0.215; and
•
the price representing a 2.5% discount to the volume weighted average price of Shares during the five trading days up
to and including the Closing Date of the SPP, rounded to the nearest half cent,
provided that the SPP Offer Price can be no lower than the lowest price permitted under ASX Listing Rule 7.2, Exception
5.
The Company is seeking to raise a capped amount of $2 million under the SPP. Applications in excess of this amount will
be scaled back at the Board’s discretion. The Directors have reserved the right to place all of the Shortfall Shares (and
attaching Options) under the SPP to sophisticated and professional investors as a separate placement, subject to approval
at the Meeting (SPP Shortfall Offer).
The SPP will not be underwritten.
The offer of New Shares under the SPP is being undertaken via this Booklet.
DRAFT
SPP Option Offer
Eligible Shareholders are also entitled to apply for one free attaching option (Option) for every two New Shares subscribed
for under the SPP via the SPP Option Offer. The Options will be exercisable at $0.30 (30 cents), expiring on 1 April 2025,
and the Company will apply for the Options to be quoted on ASX.
The SPP Option Offer is being made under a Prospectus that is being provided to Eligible Shareholders.
The SPP Option Offer is conditional on Shareholder approval at the Company’s Extraordinary General Meeting, which is
expected to be held in Melbourne on 25 May 2023 (Meeting). A separate Notice of Meeting will be dispatched to
Shareholders in connection with the Meeting, and I encourage all Shareholders to carefully read the Notice of Meeting and
vote at the Meeting.
If Shareholder approval is not obtained, or if the Options do not meet ASX’s quotation conditions, the offer and issue of
Shares under the SPP and this Booklet may proceed, however the issue Options under the SPP Option Offer and the
Prospectus may not occur. In these circumstances, SPP participants may receive New Shares under the SPP but not
Options under the SPP Option Offer.
Use of funds
The proceeds of the Capital Raising will be used as follows (assuming the full amount of $2 million is raised under the
SPP):
•
•
•
Phase 2 aGvHD clinical trial: $6.0 million;
Working Capital: $0.5 million; and
Costs of the Capital Raising: $0.5 million.
Any proceeds of the exercise of Options will be used to progress the Company’s clinical trial program and for working
capital purposes.
1
How to participate
The terms and conditions of the SPP, and details regarding how to apply, are provided in this Booklet.
You should read this Booklet (under which the SPP is being undertaken) and the accompanying Prospectus (under which
the Company is offering the Options) in its entirety before deciding whether to participate in the SPP and SPP Option
Offer.
Yours sincerely
Dr Geoff Brooke
Chairman
DRAFT
2
KEY DATES
Event
Date (2023)
SPP Record Date
Wednesday, 5 April
Capital Raising announced
Thursday, 6 April
Investor Presentation and ASX Announcement lodged with ASX
Settlement of Unconditional Placement (other than Bioscience
Managers)
Friday, 14 April
Issue and trading of Shares under the Unconditional Placement
(other than Bioscience Managers)
Monday, 17 April
Despatch of SPP Offer Booklet
Wednesday, 19 April
SPP opens
Prospectus lodged with ASIC and ASX and Options offer opens
Settlement and issue of Shares to Bioscience Managers under
Unconditional Placement
Monday, 24 April
Despatch of Notice of Meeting
Monday, 24 April
SPP closes
Monday, 8 May
Announcement of results of SPP
Wednesday, 10 May
Issue of New Shares under SPP (other than SPP Shortfall
Shares)
Thursday, 11 May
Extraordinary General Meeting
Thursday, 25 May
DRAFT
Settlement of Director Placement
Tuesday, 30 May
Allotment of Shares under the Director Placement
Wednesday, 31 May
Allotment of Options (subject to Shareholder approval and ASX
quotation condition being met)
This timetable is indicative. CYP reserves the right to vary these times and dates in its absolute discretion by sending a
revised timetable to ASX. All times are Australian Eastern Standard Time (“AEST”).
3
KEY SPP INFORMATION
The current CYP share price can be obtained from the
ASX (www.asx.com.au) and is listed in the financial and
business section of major daily newspapers circulating in
Australia.
What is the SPP?
The SPP provides Eligible Shareholders with the
opportunity to subscribe for up to $30,000 worth of New
Shares without paying any brokerage or other charges.
Is the SPP underwritten?
No, the SPP will not be underwritten at the time the SPP
offer is made, however the Company reserves the right to
subsequently put in place an underwriting for the whole or
part of the maximum amount of $2 million to be raised.
How much will the Company raise under the SPP?
CYP is seeking to raise a maximum amount of $2 million
under the SPP.
How much can I invest under the SPP?
What scale-back arrangements will apply?
Eligible Shareholders may apply for a parcel of New
Shares under the SPP in accordance with the application
amounts set out below. The maximum investment amount
under the SPP is $30,000 worth of New Shares, subject to
scale-back. In the event that CYP receives applications in
excess of the maximum amount of $2 million sought to be
raised under the SPP, it will scale back the applications.
In the event that CYP receives applications in excess of
the maximum amount sought to be raised under the SPP
(of $2 million), it will scale back applications. The basis of
scale-back will be determined by the Board at its
discretion, taking into account various factors including the
overall level of demand, the number of New Shares
applied for and the holdings of applicants.
The number of New Shares issued to an applicant will be
calculated by dividing the application monies by the final
SPP Offer Price. The table below shows how many New
Shares may be issued on the basis of different parcel sizes
at an assumed SPP Offer Price of:
SPP Shortfall Offer
In the event that less than $2 million is applied for under
the SPP, Directors have reserved the right to place all of
the shares representing the shortfall (Shortfall Shares),
and attaching Options, to any other sophisticated and
professional investors as a separate placement (SPP
Shortfall Offer).
Where the SPP Shortfall Offer exceeds the Company’s
available placement capacity, the Shortfall Shares (and
attaching Options) will only be placed if Shareholder
approval is obtained.
The SPP is being undertaken at the SPP Offer Price,
which is the lower of:
the offer price under the Placement, being $0.215;
and
•
the price representing a 2.5% discount to the volume
weighted average price of Shares during the five
trading days up to and including the Closing Date of
the SPP, rounded to the nearest half cent,
$0.215; and
•
$0.195.
DRAFT
What is the SPP Offer Price of New Shares under the
SPP?
•
•
provided that the SPP Offer Price can be no lower than the
lowest price permitted under ASX Listing Rule 7.2,
Exception 5
Application
Amount
Number of New
Shares at SPP
Offer Price of
$0.215
Number of
New Shares
at SPP Offer
Price of
$0.195
$1,000
4,652
5,129
$2,500
11,628
12,821
$5,000
23,256
25,642
$7,500
34,884
38,462
$10,000
46,512
51,283
$15,000
69,768
76,924
$20,000
93,024
102,565
$30,000
139,535
153,847
The number of New Shares will be rounded up to the
nearest whole number.
There is a risk that the market price of Shares may rise or
fall between the Record Date, the date of this Booklet, the
date on which a Shareholder makes a payment for New
Shares or (if applicable) sends in an Application Form, and
the time of issue of New Shares under the SPP. This
means that the price you pay for the New Shares issued to
you may be less than or more than the market price of
Shares at the date of this Booklet or the time of issue of
the New Shares.
Am I an Eligible Shareholder?
Participation in the SPP is optional and is available to
Shareholders who are registered holders of Shares at the
Record Date with a registered address in Australia or New
Zealand (or as otherwise determined by the Board, taking
into account disclosure requirements in relevant
jurisdictions) provided that such Shareholder is not in the
United States, or acting for the account or benefit of a
person in the United States (“Eligible Shareholder”).
Your application is unconditional and may not be
withdrawn even if the market price of Shares is less than
the SPP Offer Price.
4
The SPP is also being extended to Eligible Shareholders
who are Custodians for them to participate in the SPP on
behalf of certain Eligible Beneficiaries (who are Australian
and New Zealand residents and not in the United States,
or acting for the account or benefit of a person in the
United States) on the terms and conditions provided in this
Booklet.
under the SPP will be entitled to apply for attaching
Options.
What are the Options and what is my entitlement to
them?
The Options are free attaching options being offered to
participants in the Placement and SPP via the Prospectus.
Option holders who did not exercise their options prior to
the Record Date are not eligible to participate in the SPP in
relation to those options.
Eligible Shareholders will be entitled to apply for one
Option for every two New Shares subscribed for under the
SPP. The Options will be issued for nil cash consideration
and will be exercisable at $0.30 (30 cents), expiring on 1
April 2025. Each Option gives the holder the right to
subscribe for one Share upon exercise.
How do I apply and pay for New Shares?
If you wish to participate in the SPP, you must pay:
•
•
The offer of New Shares under the SPP is made in
accordance with ASIC Corporations (Share and Interest
Purchase Plans) Instrument 2019/547 (Instrument
2019/547) via this Booklet. Instrument 2019/547 allows a
share purchase plan to be conducted without the use of a
prospectus once in every 12-month period. The Company
satisfies the conditions of Instrument 2019/547 for the
issue of Shares under the SPP, however the Company is
unable to rely on Instrument 2019/547 for the SPP Option
Offer because the Options to be issued under the SPP
Option Offer are a new class of securities not currently
quoted on the ASX.
by BPAY®, if you are an Eligible Shareholder with a
registered address in Australia; or
via Electronic Funds Transfer, if you are an Eligible
Shareholder with a registered address in New
Zealand.
How to pay by BPAY®
Make payment by BPAY® as shown on the enclosed
Application Form. To apply via BPAY® you must have an
Australian bank account. If you apply via BPAY® there is
no need to return the enclosed Application Form, but you
will be taken to have made the statements and
certifications that are set out in the Application Form.
Accordingly, the Company is undertaking the SPP Option
Offer under this Prospectus.
Payment must be received in cleared funds by no later
than 5.00 pm (AEST) on Monday, 8 May 2023.
Payment where BPAY® is not available
The SPP Option Offer is conditional and may not
proceed
DRAFT
The offer of Options (which is governed by the Prospectus)
is conditional on obtaining Shareholder approval at the
Meeting. If Shareholder approval is not obtained, or if the
Options are not quoted, Shareholders who subscribe for
New Shares under the SPP will be issued New Shares but
will not be issued Options.
If you are an Eligible Shareholder who does not have an
Australian bank account enabled to make BPAY
payments, please make payment via EFT using the details
on your personalised Application Form.
Payment must be received in cleared funds by no later
than 5.00 pm (AEST) on Monday, 8 May 2023.
In the event of a scale-back, the number of Options issued
to you will be scaled back in the same proportion as the
number of New Shares applied for is scaled back (so that
you will be issued 50% of the number of Options as New
Shares).
Can I pay with cash, cheque, money order or card?
No, cash, cheques, money orders and card payments will
not be processed and will be returned to applicants.
How do I apply for Options?
Do I have to participate in the SPP?
Refer to the Prospectus for further details. The Application
Form allows you to apply for both New Shares (offered
under the Booklet) and attaching Options (offered under
the Prospectus).
No, participation in the SPP is entirely voluntary.
If you do not wish to participate in the SPP (and the offer of
attaching Options), do nothing.
Will the Options be quoted on ASX?
Can my offer under the SPP be transferred to a third
party?
The Company intends to seek quotation of the Options on
ASX. ASX Listing Rule 2.5, condition 6, requires that there
are at least 100,000 Options on issue and 50 holders of
Options with a marketable parcel (excluding restricted
securities). If this condition is not satisfied, the issue of
Options may not proceed.
No, the offer cannot be transferred.
What are the rights attached to New Shares issued
under the SPP?
Where can I get more information on the SPP?
New Shares issued under the SPP will rank equally with
other fully paid ordinary shares of CYP as at the date of
issue of the New Shares, except that New Shares issued
If you have questions in relation to how to participate in the
SPP, please contact the Company’s share registry,
2
Automic Registry Services, on 1300 288 664 (toll free
within Australia) or +61 2 9698 5414 (International). You
may also contact the Company Secretary on (08) 6377
8043.
Shares may change between the Record Date,
the date of the SPP Offer, the date on which the
applicant makes a BPAY® or EFT payment or
sends in an Application Form (if applicable) and
the date on which New Shares are issued to the
applicant under the SPP. The effect of this is
that the SPP Offer Price may be higher or lower
than the market price of Shares at any given
time and that Shares could be bought on-market
at a lower price than the SPP Offer Price.
If you have any questions in relation to whether an
investment in CYP through the SPP is appropriate for you,
please contact your stockbroker, accountant or other
professional adviser.
What do I do if I am a Custodian?
The SPP is being extended to Eligible Shareholders who
are Custodians (who are not in the United States, or acting
for the account or benefit of a person in the United States)
and who wish to apply for New Shares on behalf of certain
Eligible Beneficiaries.
The SPP is being offered to Custodians as the registered
Shareholder. Custodians are not required to participate on
behalf of their Eligible Beneficiaries. Custodians may
choose whether or not to extend the SPP to their Eligible
Beneficiaries.
If you wish to apply as a Custodian under the SPP to
receive New Shares for one or more Eligible Beneficiaries,
you must complete and submit an additional Custodian
Certificate before your application will be accepted.
Applications by Custodians that are not accompanied by a
duly completed Custodian Certificate will be rejected. By
applying as a Custodian on behalf of Eligible Beneficiaries
to purchase New Shares, you certify (amongst other
things) that each Eligible Beneficiary has not exceeded the
$30,000 limit.
1.4
In these terms and conditions, the “SPP Offer”
means the offer in clause 1.1.
1.5
Only persons who are Eligible Shareholders
may participate in the SPP. If you are an Eligible
Shareholder, your rights under the SPP Offer
and the SPP are personal to you and cannot be
transferred to another person.
1.6
Directors and employees of CYP who are
Eligible Shareholders may participate in the
SPP.
1.7
All references to $ or dollars in this booklet are
references to Australian dollars unless indicated
otherwise.
2.
Eligible Shareholders
2.1
Subject to the remaining paragraphs of this
clause 2, an “Eligible Shareholder” means a
registered holder of CYP Shares as at the
“Record Date” (being 7:00 pm AEST on
Wednesday, 5 April 2023) whose address, as
recorded in CYP’s register of members, is in
Australia or New Zealand (or as otherwise
determined by the Board taking into account
applicable disclosure requirements).
2.2
Option holders who did not exercise their
options prior to the Record Date are not eligible
to participate in the SPP in relation to those
options.
2.3
The New Shares to be issued under the SPP
have not been and will not be registered under
the U.S. Securities Act or the securities laws of
any state or other jurisdiction in the United
States. The New Shares may not be offered,
sold or otherwise transferred in the United
States except in a transaction exempt from, or
not subject to, the registration requirements of
the U.S. Securities Act and the applicable
securities laws of any state or other jurisdiction
in the United States. Accordingly, Shareholders
who are located in the United States or who are,
or are acting for the account or benefit of,
persons in t
Share your feedback
Discover